Sunday, May 27, 2012

New Health Canada Warning About Tysabri

Here is an interesting e-mail I received the other day:
Hello Ted,
As someone who blogs about MS, I thought you may be interested in sharing the following information with your audience.
Health Canada has approved a change to the TYSABRI Product Monograph to assist physicians and patients with multiple sclerosis (MS) make better-informed decisions about treatment with TYSABRI - for patients with relapsing-remitting form of MS. 
The new label identifies anti-JC virus (JCV) antibody status as a risk for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). 
The new label states that:
·         Anti-JCV antibody negative status indicates that exposure to the JC virus has not been detected;
·         Patients who are anti-JCV antibody positive have a higher risk of developing PML;
·         Patients who are anti-JCV antibody positive, have received prior immunosuppressant (IS) therapy and have received treatment with TYSABRI for more than two years have the highest risk of developing PML.

Kind regards,
Rick Maddalena
Do any of my readers have experience with Tysabri that they can share?

No comments:

Post a Comment